Logo image of PRFX

PAINREFORM LTD (PRFX) Stock Fundamental Analysis

NASDAQ:PRFX - Nasdaq - IL0011651580 - Common Stock - Currency: USD

3.16  -0.32 (-9.2%)

After market: 3.27 +0.11 (+3.48%)

Fundamental Rating

1

Taking everything into account, PRFX scores 1 out of 10 in our fundamental rating. PRFX was compared to 194 industry peers in the Pharmaceuticals industry. PRFX has a bad profitability rating. Also its financial health evaluation is rather negative. PRFX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year PRFX has reported negative net income.
In the past year PRFX has reported a negative cash flow from operations.
PRFX had negative earnings in each of the past 5 years.
In the past 5 years PRFX always reported negative operating cash flow.
PRFX Yearly Net Income VS EBIT VS OCF VS FCFPRFX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -2M -4M -6M -8M

1.2 Ratios

The Return On Assets of PRFX (-568.81%) is worse than 96.76% of its industry peers.
Industry RankSector Rank
ROA -568.81%
ROE N/A
ROIC N/A
ROA(3y)-67.8%
ROA(5y)-86.78%
ROE(3y)-82.98%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PRFX Yearly ROA, ROE, ROICPRFX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K -2K

1.3 Margins

PRFX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRFX Yearly Profit, Operating, Gross MarginsPRFX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023

1

2. Health

2.1 Basic Checks

Compared to 1 year ago, PRFX has less shares outstanding
PRFX has less shares outstanding than it did 5 years ago.
There is no outstanding debt for PRFX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PRFX Yearly Shares OutstandingPRFX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 200K 400K 600K 800K 1M
PRFX Yearly Total Debt VS Total AssetsPRFX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

2.2 Solvency

PRFX has an Altman-Z score of -43.95. This is a bad value and indicates that PRFX is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -43.95, PRFX is doing worse than 92.97% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -43.95
ROIC/WACCN/A
WACCN/A
PRFX Yearly LT Debt VS Equity VS FCFPRFX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 5M -5M 10M 15M

2.3 Liquidity

PRFX has a Current Ratio of 0.61. This is a bad value and indicates that PRFX is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of PRFX (0.61) is worse than 96.22% of its industry peers.
PRFX has a Quick Ratio of 0.61. This is a bad value and indicates that PRFX is not financially healthy enough and could expect problems in meeting its short term obligations.
PRFX has a Quick ratio of 0.61. This is amonst the worse of the industry: PRFX underperforms 91.35% of its industry peers.
Industry RankSector Rank
Current Ratio 0.61
Quick Ratio 0.61
PRFX Yearly Current Assets VS Current LiabilitesPRFX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

1

3. Growth

3.1 Past

The earnings per share for PRFX have decreased strongly by -1758.81% in the last year.
EPS 1Y (TTM)-1758.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1336.27%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 21.27% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y51.55%
EPS Next 2Y30.54%
EPS Next 3Y21.27%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PRFX Yearly Revenue VS EstimatesPRFX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
PRFX Yearly EPS VS EstimatesPRFX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -100 -200 -300 -400

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PRFX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRFX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRFX Price Earnings VS Forward Price EarningsPRFX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRFX Per share dataPRFX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -50 -100 -150

4.3 Compensation for Growth

PRFX's earnings are expected to grow with 21.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.54%
EPS Next 3Y21.27%

0

5. Dividend

5.1 Amount

No dividends for PRFX!.
Industry RankSector Rank
Dividend Yield N/A

PAINREFORM LTD

NASDAQ:PRFX (2/21/2025, 8:00:01 PM)

After market: 3.27 +0.11 (+3.48%)

3.16

-0.32 (-9.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-22 2024-11-22/amc
Earnings (Next)02-27 2025-02-27/amc
Inst Owners4.31%
Inst Owner Change-98.25%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.75M
Analysts43.33
Price TargetN/A
Short Float %7.62%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-39.45%
Min EPS beat(2)-67.8%
Max EPS beat(2)-11.11%
EPS beat(4)1
Avg EPS beat(4)-12.48%
Min EPS beat(4)-104.63%
Max EPS beat(4)133.61%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-300%
EPS NY rev (1m)0%
EPS NY rev (3m)-300%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-179.76
EYN/A
EPS(NY)-49.2
Fwd EYN/A
FCF(TTM)-13.09
FCFYN/A
OCF(TTM)-13.06
OCFYN/A
SpS0
BVpS-2.35
TBVpS-2.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -568.81%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-67.8%
ROA(5y)-86.78%
ROE(3y)-82.98%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 161.54%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.61
Quick Ratio 0.61
Altman-Z -43.95
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)203.33%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1758.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1336.27%
EPS Next Y51.55%
EPS Next 2Y30.54%
EPS Next 3Y21.27%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-77.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-94.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-94.91%
OCF growth 3YN/A
OCF growth 5YN/A